Common p2y13 polymorphisms are associated with plasma inhibitory factor 1 and lipoprotein(a) concentrations, heart rate and body fat mass: The GENES study.

[1]  James R. Staley,et al.  Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis , 2018, JAMA cardiology.

[2]  Sadao Takahashi.  Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation , 2017, Journal of atherosclerosis and thrombosis.

[3]  Xuebin B. Yang,et al.  Expression of P2 Purinergic Receptors in Mesenchymal Stem Cells and Their Roles in Extracellular Nucleotide Regulation of Cell Functions , 2017, Journal of cellular physiology.

[4]  J. Ruidavets,et al.  Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study , 2016, BMC Medicine.

[5]  I. Kügelgen,et al.  Pharmacology and structure of P2Y receptors , 2016, Neuropharmacology.

[6]  J. Becker,et al.  Subclinical Cardiovascular Disease and Death, Dementia, and Coronary Heart Disease in Patients 80+ Years. , 2016, Journal of the American College of Cardiology.

[7]  R. Sluyter.  P2X and P2Y receptor signaling in red blood cells , 2015, Front. Mol. Biosci..

[8]  C. Müller,et al.  P2Y₂ and Gq/G₁₁ control blood pressure by mediating endothelial mechanotransduction. , 2015, The Journal of clinical investigation.

[9]  L. Martinez,et al.  Increased atherosclerosis in P2Y13/apolipoprotein E double-knockout mice: contribution of P2Y13 to reverse cholesterol transport. , 2015, Cardiovascular research.

[10]  L. Martinez,et al.  Role of the ubiquitin–proteasome system in the regulation of P2Y13 receptor expression: impact on hepatic HDL uptake , 2014, Cellular and Molecular Life Sciences.

[11]  N. Lalwani,et al.  P2Y13 Receptor Regulates HDL Metabolism and Atherosclerosis In Vivo , 2014, PloS one.

[12]  A. Gartland,et al.  Role of the P2Y13 Receptor in the Differentiation of Bone Marrow Stromal Cells into Osteoblasts and Adipocytes , 2013, Stem cells.

[13]  L. Martinez,et al.  Lack of P2Y13 in mice fed a high cholesterol diet results in decreased hepatic cholesterol content, biliary lipid secretion and reverse cholesterol transport , 2013, Nutrition & Metabolism.

[14]  L. Becker,et al.  Scavenger receptor-BI is a receptor for lipoprotein(a) , 2013, Journal of Lipid Research.

[15]  J. Ruidavets,et al.  Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study[S] , 2013, Journal of Lipid Research.

[16]  J. Ruidavets,et al.  Association of Hepatic Lipase -514T Allele with Coronary Artery Disease and Ankle-Brachial Index, Dependence on the Lipoprotein Phenotype: The GENES Study , 2013, PloS one.

[17]  L. Martinez,et al.  Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion. , 2013, Biochimica et biophysica acta.

[18]  M. Billaud,et al.  Mechanisms of ATP release and signalling in the blood vessel wall. , 2012, Cardiovascular research.

[19]  C. Kimchi-Sarfaty,et al.  Understanding the contribution of synonymous mutations to human disease , 2011, Nature Reviews Genetics.

[20]  J. Ruidavets,et al.  Mitochondrial Inhibitory Factor 1 (IF1) Is Present in Human Serum and Is Positively Correlated with HDL-Cholesterol , 2011, PloS one.

[21]  Rei-Cheng Yang,et al.  Hypoxia-Inducible Factor 1&agr; Regulates the Expression of the Mitochondrial ATPase Inhibitor Protein (IF1) in Rat Liver , 2011, Shock.

[22]  M. Champy,et al.  Altered lipoprotein metabolism in P2Y(13) knockout mice. , 2010, Biochimica et biophysica acta.

[23]  L. Martinez,et al.  P2Y13 receptor is critical for reverse cholesterol transport , 2010, Hepatology.

[24]  J. Guindo,et al.  Impact of clinical and subclinical peripheral arterial disease in mid-term prognosis of patients with acute coronary syndrome. , 2009, The American journal of cardiology.

[25]  W. Engels.  Exact Tests for Hardy–Weinberg Proportions , 2009, Genetics.

[26]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[27]  M. Ridderstråle,et al.  The P2Y13 Met-158-Thr Polymorphism, Which Is in Linkage Disequilibrium with the P2Y12 Locus, Is Not Associated with Acute Myocardial Infarction , 2008, PloS one.

[28]  G. Burnstock,et al.  P2 receptors in cardiovascular regulation and disease , 2008, Purinergic Signalling.

[29]  Pier Franco Pignatti,et al.  Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease , 2007, BMC Medical Genetics.

[30]  H. Bloomfield,et al.  LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. , 2006, Atherosclerosis.

[31]  J. Ando,et al.  Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice , 2006, Nature Medicine.

[32]  L. Martinez,et al.  The nucleotide receptor P2Y13 is a key regulator of hepatic High-Density Lipoprotein (HDL) endocytosis , 2005, Cellular and Molecular Life Sciences CMLS.

[33]  D. Erlinge,et al.  ADP Acting on P2Y13 Receptors Is a Negative Feedback Pathway for ATP Release From Human Red Blood Cells , 2005, Circulation research.

[34]  P. Fontana,et al.  P2Y12 H2 Haplotype Is Associated With Peripheral Arterial Disease: A Case-Control Study , 2003, Circulation.

[35]  P. Fontana,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003, Circulation.

[36]  Xavier Collet,et al.  Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis , 2003, Nature.

[37]  F. Monsma,et al.  P2Y13: Identification and characterization of a novel Gαi-coupled ADP receptor from human and mouse , 2002 .

[38]  M. Parmentier,et al.  Identification of a Novel Human ADP Receptor Coupled to Gi * , 2001, The Journal of Biological Chemistry.

[39]  Y. Marcel,et al.  Biochemical and physical properties of remnant-HDL2 and of pre beta 1-HDL produced by hepatic lipase. , 1999, Biochemistry.

[40]  Y. Hellsten,et al.  Adenosine concentrations in the interstitium of resting and contracting human skeletal muscle. , 1998, Circulation.

[41]  G. Kostner,et al.  Interaction of lipoprotein Lp[a] with the B/E-receptor: a study using isolated bovine adrenal cortex and human fibroblast receptors. , 1990, Journal of lipid research.

[42]  J. Breslow,et al.  Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. , 1989, The Journal of clinical investigation.

[43]  B. Gordon,et al.  Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[44]  L. Martinez,et al.  RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. , 2009, Cellular signalling.

[45]  M. Koschinsky,et al.  Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator. , 1994, Chemistry and physics of lipids.